Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Research Associates, Inc

Neither a doctor nor a teaching hospital

Research payments

$334,409

47 payments

Through program year 2025, Central Research Associates, Inc is reported as receiving $334,409 in research payments, across 47 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $17,779 5
2024 Research $13,655 4
2023 Research $1,313 2
2022 Research $70,077 6
2021 Research $35,426 7
2020 Research $22,734 8
2019 Research $173,425 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $291,780 23 payments
  2. Flexion Therapeutics, Inc. $20,546 2 payments
  3. AstraZeneca Pharmaceuticals LP $16,342 2 payments
  4. Novo Nordisk AS $2,703 16 payments
  5. AstraZeneca UK Limited $1,726 2 payments
  6. Novartis Pharmaceuticals Corporation $1,313 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $191,323 5 payments
  2. Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $45,666 6 payments
  3. A Phase 3, 12 Month, Open Label Study of Lasmiditan in Pediatric Patients With Migraine Pioneer Peds2 $36,705 6 payments
  4. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $18,068 4 payments
  5. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone Or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity Or Overweight Without Type 2 Diabetes $13,755 2 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis $11,000 1 payment
  7. Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee $9,546 1 payment
  8. Nn9535-4506 $2,703 16 payments
  9. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (Surmount-Adolescents-2) $2,651 1 payment
  10. Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate Ly4065967 for the Treatment of Diabetic Peripheral Neuropathic Pain $1,021 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record